Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, Carl H, Warshauer, Jeremy T, Bluestone, Jeffrey A·2017·Nature Medicine
DOI 10.1038/nm.4321

Cited by (445)

Items 101–200 of 445

  1. Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise
    Sanjna Nilesh Nerurkar, Denise L M Goh, Chun Chau Lawrence Cheung, Pei Qi Yvonne Nga, Jeffrey Chun Tatt Lim, Joe Poh-Sheng Yeong · 2020 · Cancers
  2. Cancer immunotherapy-associated hypophysitis
    Cinzia Solinas, Michele Porcu, Pushpamali De Silva, Marco Musi, Sandrine Aspeslagh, Mario Scartozzi, Karen E Willard-Gallo, Stefano Mariotti, Luca Saba · 2018 · Seminars in Oncology
  3. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
    Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, Md. Rezaul Islam, Md. Rezaul Islam, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya, SIMONA GABRIELA BUNGAU · 2022 · Molecules
  4. mTOR signaling in immune cells and its implications for cancer immunotherapy
    Hu Zeng · 2017 · Cancer Letters
  5. Cancer Immunoediting by Innate Lymphoid Cells
    Marek Wagner, Shigeo Koyasu · 2019 · Trends in Immunology
  6. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
    Charles‐Henri Wassmer, Sofia El Hajji, Xenofon Papazarkadas, Philippe Compagnon, Parissa Tabrizian, Stéphanie Lacotte, Christian Toso · 2023 · Cancers
  7. Peripheral nervous system immune-related adverse events due to checkpoint inhibition
    Méabh O’Hare, Amanda C. Guidon · 2024 · Nature Reviews Neurology
  8. Targeting the MHC Ligandome by Use of TCR-Like Antibodies
    Lene Støkken Høydahl, Rahel Frick, Inger Sandlie, Geir Åge Løset · 2019 · Antibodies
  9. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
    Eun Sook Lee, Jung Min Shin, Soyoung Son, Hyewon Ko, Wooram Um, Seok Ho Song, Jae Ah Lee, Jae Hyung Park · 2019 · Advanced Healthcare Materials
  10. Bioresponsive Immunotherapeutic Materials
    Jinpeng Han, Tao Sheng, Yuqi Zhang, Hao Cheng, Jianqing Gao, Jicheng Yu, Zhen Gu · 2023 · Advanced Materials
  11. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors
    Isabel Mazarico, Ismael Capel, Olga Giménez‐Palop, Lara Albert, Irene Berges, F. Luchtenberg, Yolanda García García, Luis Antonio Fernandez-Morales, Victor José de Pedro, Assumpta Caixàs et al. · 2019 · Journal of Endocrinological Investigation
  12. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy
    Wenjie Zhai, Xiuman Zhou, Mingxia Zhai, Wanqiong Li, Yunhui Ran, Yixuan Sun, Jiangfeng Du, Wenshan Zhao, Lingxiao Xing, Yuanming Qi et al. · 2020 · Science China Life Sciences
  13. Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
    Zoe Quandt, Arabella Young, Ana Luisa Perdigoto, Kevan C. Herold, Mark Stuart Anderson · 2020 · Annual Review of Medicine
  14. The Adrenal Cortex and its Disorders
    Walter L. Miller · 2009 · Wiley eBooks
  15. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
    Juhi R. Kuchroo, David A. Hafler, Arlene H. Sharpe, Liliana E. Lucca · 2021 · Science Immunology
  16. Metformin-Mediated Fast Charge-Reversal Nanohybrid for Deep Penetration Piezocatalysis-Augmented Chemodynamic Immunotherapy of Cancer
    Yuan Wang, Qingshuang Tang, Ruiqi Wu, Shiyuan Yang, Zhishuai Geng, Ping He, Xiaoda Li, Qingfeng Chen, Xiaolong Liang · 2024 · ACS Nano
  17. Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
    Rafael A. Cubas, Zia Khan, Qian Gong, Марина Москаленко, Huizhong Xiong, Qinglin Ou, Christine Pai, Ryan Rodriguez, Jeanne Cheung, Andrew C. Chan · 2020 · Journal for ImmunoTherapy of Cancer
  18. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
    Maria Grigoriou, Aggelos Banos, Aikaterini Hatzioannou, Andreas Kloetgen, Panagiotis Kouzis, Despoina Aggouraki, Roubini Zakopoulou, Giorgos Bamias, Eva N. Kassi, Dimitriοs Mavroudis et al. · 2021 · Cancer Immunology Research
  19. Understanding adverse events of immunotherapy: A mechanistic perspective
    Kelly P. Burke, Stephanie Grebinoski, Arlene H. Sharpe, Dario A.A. Vignali · 2020 · The Journal of Experimental Medicine
  20. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy
    Bo Zhu, Hang Yin, Di Zhang, Meiling Zhang, Xiaojuan Chao, Luca Scimeca, Ming-Ru Wu · 2024 · Cellular and Molecular Immunology
  21. Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
    Wei Li, Tae In Kim, Ji Hye Kim, Hwan‐Suck Chung · 2019 · Molecules
  22. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
    Derek VanDyke, Marcos Iglesias, Jakub Tomala, Arabella Young, Jennifer Smith, Joseph A. Perry, Edward Gebara, Amy Rachael Cross, Laurene S. Cheung, Arbor G. Dykema et al. · 2022 · Cell Reports
  23. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
    Xinyu Guo, Shi Chen, Xueyan Wang, Xiaowei Liu · 2023 · Frontiers in Immunology
  24. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis
    Susanna Jeurling, Laura C. Cappelli · 2020 · Current Opinion in Rheumatology
  25. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
    Leilei Wu, Zhenshan Zhang, Menglin Bai, Yujie Yan, Jinming Yu, Yaping Xu · 2023 · Cell Communication and Signaling
  26. Neutrophil infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR phototherapy to enhance antitumor immune response and T cell immune memory
    Shuhong Qi, Lisen Lu, Feifan Zhou, Yuzhou Chen, Mengli Xu, Lu Chen, Yu Xiang, Wei R. Chen, Zhihong Zhang · 2020 · Theranostics
  27. Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy
    Cong-Shan Yuan, Ya Liu, Ting Wang, Mengjie Sun, Xiguang Chen · 2020 · ACS Biomaterials Science & Engineering
  28. Research Progress of Conjugated Nanomedicine for Cancer Treatment
    Bin Zhao, Sa Chen, Ye Hong, Liangliang Jia, Ying Yin Zhou, Xinyu He, Ying Wang, Zhongmin Tian, Zhe Yang, Di Gao · 2022 · Pharmaceutics
  29. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update
    Quang Minh Dang, Ryu Watanabe, Mayu Shiomi, Kazuo Fukumoto, Tomomi W. Nobashi, Tadashi Okano, Shinsuke Yamada, Motomu Hashimoto · 2023 · International Journal of Molecular Sciences
  30. Eicosanoid and Specialized Proresolving Mediator Regulation of Lymphoid Cells
    Jessica Wei, Karsten Gronert · 2018 · Trends in Biochemical Sciences
  31. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
    Chen Ning Zhao, Arun Rajan · 2019 · Mediastinum
  32. Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism
    Larissa Bastos Costa, Marcelo Araujo Queiroz, Felipe de Galiza Barbosa, Rafael Fernandes Nunes, Elaine C. Zaniboni, Mariana Ferraz de Campos Mazo Ruiz, Denis L. Fontes Jardim, José Flávio Gomes Marin, Giovanni Guido Cerri, Carlos Alberto Buchpiguel · 2020 · Radiographics
  33. Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy
    Shunzhe Zheng, Guanting Li, Jianbin Shi, Xinying Liu, Meng Li, Zhonggui He, Chutong Tian, Ken‐ichiro Kamei · 2023 · Journal of Controlled Release
  34. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
    Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell · 2018 · Genome Medicine
  35. Cancer Immunotherapy-Associated Hypophysitis
    Franklin Castillero, O. Castillo, Geiner Jiménez Jiménez, José-Manuel Fallas-Ramirez, Marco Polo Peralta Álvarez, Oscar G. Arrieta · 2019 · Future Oncology
  36. Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives
    Ramar Thangam, Kapil Dev Patel, Heemin Kang, Ramasamy Paulmurugan · 2021 · Vaccines
  37. The Folate Cycle As a Cause of Natural Killer Cell Dysfunction and Viral Etiology in Type 1 Diabetes
    Allison L. Bayer, Christopher A. Fraker · 2017 · Frontiers in Endocrinology
  38. Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes
    Paola Di Bonito, Luisa Accardi, Luisa Galati, Flavia Ferrantelli, Maurizio Federico · 2019 · Cancers
  39. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
    Yin Wu, Dhruva Biswas, Charles Swanton · 2021 · Seminars in Cancer Biology
  40. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
    Yun Yu Hu, Sébastien Paris, Genevieve Bertolet, Hampartsoum B. Barsoumian, Kewen He, Duygu Sezen, Dawei Chen, Mark D. Wasley, Jordan DA SILVA, Joylise Mitchell et al. · 2022 · Journal of Nanobiotechnology
  41. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
    Sajad Najafi, Keywan Mortezaee · 2023 · Life Sciences
  42. Checks and Balances in Autoimmune Vasculitis
    Rebeca Hid Cadena, Wayel Habib Abdulahad, Geke A.P. Hospers, Thijs T. Wind, Annemieke M. H. Boots, Peter Heeringa, Elisabeth Brouwer · 2018 · Frontiers in Immunology
  43. Microbiota — an amplifier of autoimmunity
    Alexis Vogelzang, Matteo Maurizio Guerrini, Nagahiro Minato, Sidonia Fagarasan · 2018 · Current Opinion in Immunology
  44. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
    Brendan D. Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy C. Gregory et al. · 2017 · Journal for ImmunoTherapy of Cancer
  45. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities
    Thomas Shum, Robert L. Kruse, Cliona M. Rooney · 2018 · Expert Opinion on Biological Therapy
  46. Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
    Kyung Hwan Kim, Chang Gon Kim, Eui‐Cheol Shin · 2020 · Immune Network
  47. Polymersomes as a potential platform for cancer immunotherapy
    Jari F. Scheerstra, Annelies C. Wauters, Jurjen Tel, Loai K. E. A. Abdelmohsen, Jan C. M. van Hest · 2021 · Materials Today Advances
  48. Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
    Vanessa Acebes-Fernández, Alicia Landeira‐Viñuela, Pablo Juanes‐Velasco, Ángela‐Patricia Hernández, Andrea Otazo‐Pérez, Raúl Manzano-Román, Rafael Góngora, Manuel Fuentes · 2020 · Nanomaterials
  49. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
    Noelia Vilariño, Jordi Bruna, Foteini Kalofonou, Garifallia G. Anastopoulou, Andreas A. Argyriou · 2020 · International Journal of Molecular Sciences
  50. The emergence of cancer sono-immunotherapy
    Yuqi Yang, Yuan Cheng, Liang Cheng · 2024 · Trends in Immunology
  51. Innovative hydrogel-based delivery systems for immunotherapy: A review of pre-clinical progress
    Narsimha Mamidi, Michael J. Poellmann, Kaila Javius-Jones, KiChang Nam, Seungpyo Hong · 2024 · Nano Research
  52. Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study
    Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura et al. · 2023 · Cancer Medicine
  53. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD ‐1, TIGIT , and TIM ‐3 in Lymphocytes From Patients With Systemic Sclerosis
    Michelle Fleury, Anna C. Belkina, Elizabeth A. Proctor, Christopher A. Zammitti, Robert W. Simms, Douglas A. Lauffenburger, Jennifer E Snyder-Cappione, Robert Lafyatis, Hans Dooms · 2017 · Arthritis & Rheumatology
  54. Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
    Ralf Kleef, Ralph W. Moss, Attila Marcell Szász, Arthur Bohdjalian, Hans Bojar, Tibor Bakács · 2018 · Integrative Cancer Therapies
  55. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
    Yan Ma, Xiao Ma, Jingting Wang, Shanshan Wu, Jing Wang, Bangwei Cao · 2022 · World Journal of Surgical Oncology
  56. Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: a translational study from chronic life stress to brain injury
    Hong Pan, Agnes A. Steixner-Kumar, Anna Seelbach, Nadine R. Deutsch, Anja Ronnenberg, Daniel Tapken, Nico von Ahsen, Marina Mitjans, Hans Worthmann, Ralf Trippe et al. · 2020 · Molecular Psychiatry
  57. Big Data Approaches for Modeling Response and Resistance to Cancer Drugs
    Peng Jiang, William R. Sellers, X. Shirley Liu · 2018 · Annual Review of Biomedical Data Science
  58. The role of RICTOR amplification in targeted therapy and drug resistance
    Deze Zhao, Man Jiang, Xiaochun Zhang, Helei Hou · 2020 · Molecular Medicine
  59. Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations
    Elisa Gremese, Stefano Alivernini, Edoardo Sean Ferraccioli, Gianfranco Ferraccioli · 2020 · Clinical Immunology
  60. Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment
    Jean-Philippe Bastien, Annabelle Minguy, Vibhuti P. Davé, Denis‐Claude Roy · 2019 · Seminars in Immunology
  61. Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
    Ting Yan, Lun Yu, Jiwen Zhang, Yun Chen, Yilan Fu, Jingyi Tang, Dehua Liao · 2024 · Frontiers in Immunology
  62. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells
    Beatrice Claudia Cianciotti, Zulma Irene Magnani, Alessia Ugolini, Barbara Camisa, Ivan Merelli, Valentina Vavassori, Alessia Potenza, Antonio Imparato, Francesco Manfredi, Danilo Abbati et al. · 2024 · Frontiers in Immunology
  63. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
    David M. Richards, Viola Marschall, Katharina Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke et al. · 2019 · Journal for ImmunoTherapy of Cancer
  64. Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
    Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao · 2022 · Human Vaccines & Immunotherapeutics
  65. Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches
    Susmita Aryal, Sanghyo Park, Hyungkyu Park, Chaewon Park, Woo Cheol Kim, Deepika Thakur, Young‐Joo Won, Jaehong Key · 2023 · International Journal of Nanomedicine
  66. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
    Maria V. Deligiorgi, Gerasimos Siasos, Chrysovalantis Vergadis, Dimitrios T. Trafalis · 2020 · International Immunopharmacology
  67. Managing side effects of immune checkpoint inhibitors in breast cancer
    Carmen Criscitiello, Chiara Corti, Gabriella Pravettoni, Giuseppe Curigliano · 2021 · Critical Reviews in Oncology/Hematology
  68. Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
    Emanuela Guerra, Roberta Di Pietro, Mariangela Basile, Marco Trerotola, Saverio Alberti · 2021 · International Journal of Molecular Sciences
  69. Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
    Yoshiaki Yura, Masakazu Hamada · 2022 · Cancers
  70. Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines
    Jason M. Miska, Jen Bon Lui, Kevin H. Toomer, Priyadharshini Devarajan, Xiaodong Cai, JeanMarie Houghton, Diana M. Lopez, Maria Teresa Abreu, Gaofeng Wang, Zhibin Chen · 2018 · The Journal of Experimental Medicine
  71. Immune checkpoints and cancer in the immunogenomics era
    Ryan M. Park, Mary Winnicki, Evan Liu, Wen‐Ming Chu · 2018 · Briefings in Functional Genomics
  72. Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer
    Tibor Bakács, Ralph W. Moss, Ralf Kleef, Marcell A. Szász, Colin C. Anderson · 2019 · Scandinavian Journal of Immunology
  73. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
    Mau‐Shin Chi, Minesh P. Mehta, Kai-Lin Yang, Hung-Chih Lai, Ying‐Chu Lin, Hui-Ling Ko, Yu‐Shan Wang, Kuang‐Wen Liao, Kwan-Hwa Chi · 2020 · Frontiers in Oncology
  74. Immunotherapy for thymoma
    Marko Jakopović, Lela Bitar, Fran Seiwerth, Ante Marušić, Kristina Krpina, Miroslav Samaržija · 2020 · Journal of Thoracic Disease
  75. Ternary Regulation of Tumor Microenvironment by Heparanase‐Sensitive Micelle‐Loaded Monocytes Improves Chemo‐Immunotherapy of Metastatic Breast Cancer
    Tianqun Lang, Zhong Zheng, Xin Yi Huang, Yiran Liu, Yihui Zhai, Pengcheng Zhang, Yaping Li, Qi Yin · 2020 · Advanced Functional Materials
  76. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
    Guacimara Ortega Sánchez, Kathleen Jahn, Spasenija Savic, Alfred Zippelius, Heinz Philipp Laubli · 2018 · Journal for ImmunoTherapy of Cancer
  77. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy
    Masaki Maruta, Toshiki Ochi, Kazushi Tanimoto, Hiroaki Asai, Takashi Saitou, Hiroshi Fujiwara, Takeshi Imamura, Katsuto Takenaka, Masaki Yasukawa · 2019 · Scientific Reports
  78. The development of human immune system mice and their use to study tolerance and autoimmunity
    Thiago Alves da Costa, Julie Lang, Raul Martin Torres, Roberta Pelanda · 2019 · Journal of Translational Autoimmunity
  79. Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy
    Wenlu Yan, Tianqun Lang, Xian Qi, Yaping Li · 2020 · Current Opinion in Biotechnology
  80. PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy
    Brenson A. Jassim, Jianping Lin, Zhong‐Yin Zhang · 2022 · Expert Opinion on Drug Discovery
  81. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
    Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi · 2023 · International Journal of Molecular Sciences
  82. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis
    S. H. Verspohl, Tobias A.W. Holderried, Charlotte Behning, Peter Brossart, Valentin Sebastian Schäfer · 2021 · Therapeutic Advances in Musculoskeletal Disease
  83. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
    Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Xiuli Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan et al. · 2021 · Frontiers in Medicine
  84. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
    Bryan Eric Strauss, Gissele Rolemberg Oliveira Silva, Igor de Luna Vieira, Otto Luiz Dutra Cerqueira, Paulo Roberto Del Valle, Ruan F.V. Medrano, Samir Andrade Mendonça · 2018 · Clinics
  85. Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion
    Alessandro Ascione, Claudia Arenaccio, Alessandra Mallano, Michela Flego, Mara Gellini, Mauro Andreotti, Craig W. Fenwick, Giuseppe Pantaleo, Stefano Vella, Maurizio Federico · 2019 · BMC Biotechnology
  86. Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy
    Hongyi Chen, Tao Sun, Chen Jiang · 2022 · Journal of Controlled Release
  87. Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy
    Wenlu Yan, Tianqun Lang, Wenhui Yuan, Qi Yin, Yaping Li · 2022 · Acta Pharmacologica Sinica
  88. Role of B cells in immune‐related adverse events following checkpoint blockade
    Kavita M. Dhodapkar, Alyssa M. Duffy, Madhav V. Dhodapkar · 2023 · Immunological Reviews
  89. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma
    Xier Pan, Shuting Ni, Kaili Hu · 2024 · Biomaterials
  90. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma
    Οlga E. Makri, Foteinos-Ioannis D. Dimitrakopoulos, Foteini N. Tsapardoni, Iasonas K. Tsekouras, Andreas A. Argyriou, Haralabos P. Kalofonos, Constantine D. Georgakopoulos · 2020 · International Journal of Neuroscience
  91. Pan-cancer analysis of neoepitopes
    Gabriel Teku, Mauno Vihinen · 2018 · Scientific Reports
  92. Tipping the balance: inhibitory checkpoints in intestinal homeostasis
    Maria E. Joosse, Iris Nederlof, Lucy S. K. Walker, Janneke N. Samsom · 2018 · Mucosal Immunology
  93. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
    Reza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, Narges Baluch, Neda Ashayeri, Sushil Kumar, Hai‐Ling Margaret Cheng, Herman Yeger, Bikul Das, Myron R. Szewczuk · 2021 · Cancers
  94. Association between germ-line HLA and immune-related adverse events
    Ning Jiang, Yue Yu, Min Zhang, Yu Tang, Dawei Wu, Shuhang Wang, Yuan Fang, Yu Zhang, Lin Meng, Yingying Li et al. · 2022 · Frontiers in Immunology
  95. Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds
    Elahe Minaei, Marie Ranson, Morteza Aghmesheh, Ronald Sluyter, Kara L. Vine · 2024 · Journal of Controlled Release
  96. A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.
    Bengang Wang, Xiangjun Hao, Jinshan Yan, Xin Li, Mingfang Zhao, Tao Han · 2024 · PubMed Central
  97. Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology
    Joseph H. Choe, Jasper Z. Williams, Wendell A. Lim · 2020 · Annual Review of Cancer Biology
  98. The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
    Olav Dahl, Marianne Brydøy · 2019 · Acta Oncologica
  99. Computational Verification of Large Logical Models—Application to the Prediction of T Cell Response to Checkpoint Inhibitors
    Céline Hernandez, Morgane Thomas‐Chollier, Aurélien Naldi, Denis Thieffry · 2020 · Frontiers in Physiology
  100. Tackling cancer cell dormancy: Insights from immune models, and transplantation
    Alexandre Corthay, Tibor Bakács, Govindarajan Thangavelu, Colin C. Anderson · 2021 · Seminars in Cancer Biology